Overview

The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression

Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the safety and effectiveness of the combination of aripiprazole (Abilify) and selective serotonin reuptake inhibitors (SSRIs) in subjects with psychotic major depression.
Phase:
Phase 3
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborator:
Bristol-Myers Squibb
Treatments:
Antidepressive Agents
Aripiprazole
Serotonin
Serotonin Uptake Inhibitors